Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
| ▸ | CCR3 | P51677 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 3/20 | 0.35 |
| ▸ | HRH2 | P25021 | 2/20 | 0.35 |
| ▸ | HRH1 | P35367 | 2/20 | 0.35 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.34 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 2/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | FPR2 | P25090 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6094385 | 0.91 | CCR3 (0.40) | CCR3MEN1KMT2AARHRH2 | |
| SCHEMBL6986200 | 0.89 | CCR3 (0.39) | CCR3MEN1KMT2AARHRH2 | |
| SCHEMBL2966214 | 0.89 | KCNH2 (0.44) | KCNH2CCR3MEN1KMT2AHRH2 | |
| SCHEMBL2967483 | 0.86 | KCNH2 (0.48) | KCNH2CCR3MEN1KMT2AHRH2 | |
| SCHEMBL2956478 | 0.84 | KDM4E (0.38) | MEN1KMT2AAR | |
| SCHEMBL3126044 | 0.84 | KCNH2 (0.45) | KCNH2CCR3RORCFPR2DRD2 | |
| SCHEMBL2958763 | 0.84 | KCNH2 (0.44) | KCNH2CCR3MEN1KMT2AHRH2 | |
| SCHEMBL2967583 | 0.84 | KCNH2 (0.45) | KCNH2CCR3MEN1KMT2AHRH2 | |
| SCHEMBL2970015 | 0.84 | KCNH2 (0.45) | KCNH2CCR3MEN1KMT2AAR | |
| SCHEMBL5965408 | 0.84 | AR (0.41) | CCR3MEN1ARHRH2HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036675-A1 | New process for production of oxabispidines | ASTRAZENECA AB (SE) | 2009-02-05 | — | — | US | claimed |
| EP-1900741-A1 | New process for the production of oxabispidines | AstraZeneca AB (SE) | 2008-03-19 | — | — | EP | claimed |
| US-7217708-B2 | Cardiovascular disorders | ASTRAZENECA AB (SE) | 2007-05-15 | — | — | US | claimed |
| EP-1389212-B1 | 3,7-DIAZABICYCLO 3.3.1| FORMULATIONS AS ANTI-ARRYTHMIC COMPOUNDS | ASTRAZENECA AB (SE) | 2006-07-12 | — | — | EP | claimed |
| EP-1389213-B1 | 3,7-DIAZABICYCLO 3.3.1| FORMULATIONS AS ANTIARHYTHMIC COMPOUNDS | ASTRAZENECA AB (SE) | 2006-04-12 | — | — | EP | claimed |
| EP-1401502-B1 | PHARMACEUTICAL FORMULATION COMPRISING IOTA-CARRAGEENAN AND AT LEAST ONE NEUTRAL GELLING POLYMER | ASTRAZENECA AB (SE) | 2005-12-28 | — | — | EP | claimed |
| EP-1559717-A2 | Oxabispidine compounds useful in the treatment of cardiac arrythmias | AstraZeneca AB (SE) | 2005-08-03 | — | — | EP | claimed |
| EP-1550663-A1 | New crystalline forms of antiarrhythmic compounds | Astra Zeneca AB (SE) | 2005-07-06 | — | — | EP | claimed |
| EP-1235831-B1 | NEW OXABISPIDINE COMPOUNDS USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2005-03-30 | — | — | EP | claimed |
| US-20050037067-A1 | 3,7-Diazabicyclo [3.3.1]formulations as anti-arrhythmic compounds | ASTRAZENECA AB (SE) | 2005-02-17 | — | — | US | claimed |
| EP-1389212-A1 | 3,7-DIAZABICYCLO 3.3.1] FORMULATIONS AS ANTI-ARRYTHMIC COMPOUNDS | AstraZeneca AB (SE) | 2004-02-18 | — | — | EP | claimed |
| EP-1389211-A1 | 3,7-DIAZYBICYCLO 3.3.1] FORMULATIONS AS ANTIARRHYTMIC COMPOUNDS | AstraZeneca AB (SE) | 2004-02-18 | — | — | EP | claimed |
| US-20030153564-A1 | New oxabispidine compounds useful in the treatment of cardiac arrhythmias | ASTRAZENECA AB | 2003-08-14 | — | — | US | claimed |
| EP-1330461-A1 | NEW OXABISPIDINE COMPOUND USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | AstraZeneca AB (SE) | 2003-07-30 | — | — | EP | claimed |
| US-6559143-B1 | Class III electrophysiological activity, drugs which prolong the trans-membrane action potential duration and refractoriness, without affecting cardiac conduction | ASTRAZENECA AB (SE) | 2003-05-06 | — | — | US | claimed |
| WO-2003000293-A1 | PHARMACEUTICAL FORMULATION | ASTRAZENECA AB (SE) | 2003-01-03 | — | — | WO | claimed |
| WO-2002083687-A1 | 3,7-DIAZYBICYCLO [3.3.1] FORMULATIONS AS ANTIARRHYTMIC COMPOUNDS | ASTRAZENECA AB (SE) | 2002-10-24 | — | — | WO | claimed |
| WO-2002083688-A1 | 3,7-DIAZABICYCLO [3.3.1] FORMULATIONS AS ANTIARHYTHMIC COMPOUNDS | ASTRAZENECA AB (SE) | 2002-10-24 | — | — | WO | claimed |
| WO-2002083689-A1 | 3,7-DIAZABICYCLO [3.3.1] FORMULATIONS AS ANTI-ARRYTHMIC COMPOUNDS | ASTRAZENECA AB (SE) | 2002-10-24 | — | — | WO | claimed |
| WO-2002028863-A1 | NEW OXABISPIDINE COMPOUND USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2002-04-11 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153564-A1 | New oxabispidine compounds useful in the treatment of cardiac arrhythmias | KCNH1, CACNA1E, RYR1 | KCNH2 9/4885CCR3 3660/4885MEN1 2766/4885 |
| US-20050037067-A1 | 3,7-Diazabicyclo [3.3.1]formulations as anti-arrhythmic compounds | CACNA1G, CACNA1I, CACNA1B | KCNH2 29/4885CCR3 2086/4885MEN1 4114/4885 |
| US-20090036675-A1 | New process for production of oxabispidines | AVPR1B, CCNB1, DHPS | KCNH2 424/4885CCR3 3095/4885MEN1 2977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.